StreetInsider.com News Articles

Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald

Wed, 03 Jun 2026 06:48:43 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ideaya Biosciences (NASDAQ: IDYA).

The analyst commented, "We hosted CEO Yujiro Hata, CMO Darrrin Beaupre, CCO Stu Dorman, and SVP of clinical dev Jasgit Sachdev for a wellattended dinner at ASCO (6/1). It was on the back of darovasertib's (daro) Ph2/3 OptimUM-02 data presentation as a latebreaker abstract at the conference, a monumental milestone for IDEAYA as a company, and for patients with metastatic uveal melanoma (MUM). Not surprisingly, there was a fair amount of discussion on the approval and launch details of daro in 1L MUM. What's a little surprising

Form 8-K IDEAYA Biosciences, Inc. For: Jun 03

Wed, 03 Jun 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260603/26594891.html

Form 8-K IDEAYA Biosciences, Inc. For: Jun 03

Wed, 03 Jun 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260603/26594891.html

IDEAYA Biosciences partners with Roche for pancreatic cancer study

Wed, 03 Jun 2026 06:00:41 -0400

IDEAYA Biosciences Inc. (NASDAQ: IDYA) entered into a clinical collaboration with Roche to evaluate a combination therapy for patients with pancreatic ductal adenocarcinoma that carries specific genetic mutations.

The collaboration will test IDE892, IDEAYA's investigational PRMT5 inhibitor currently in Phase 1 trials, combined with RG6505, Roche's Phase 1 pan-RAS inhibitor. The study targets patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.

IDEAYA will sponsor the clinical trial while Roche will supply RG6505. Both companies will maintain joint governance to oversee the study and retain all commercial rights to their respective compounds.

MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma cases, according

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Wed, 03 Jun 2026 06:00:00 -0400

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
MTAP-deletion is estimated to occur in up to 40% of PDAC

SOUTH SAN FRANCISCO, Calif., June 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Wed, 03 Jun 2026 06:00:00 -0400

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
MTAP-deletion is estimated to occur in up to 40% of PDAC

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Wed, 03 Jun 2026 06:00:00 -0400

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
MTAP-deletion is estimated to occur in up to 40% of PDAC

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Wed, 03 Jun 2026 06:00:00 -0400

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
MTAP-deletion is estimated to occur in up to 40% of PDAC

Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens

Tue, 02 Jun 2026 04:30:01 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $45.00 price target on Ideaya Biosciences (NASDAQ: IDYA).

The analyst commented, "IDEAYA Biosciences' ASCO update on OptimUM-02 data provided additional color on the strength of results, including safety and a highly favorable serious adverse event profile compared to checkpoint inhibitors. We highlight that the ~7-month PFS value is >2.2 times the current SoC, significant progress in the management of metastatic uveal melanoma (MUM). IDYA is moving toward regulatory approval via the RTOR process, expected to complete in 2H26 and set up a potential 2027 launch. We maintain our Market Outperform rating

Form 8-K IDEAYA Biosciences, Inc. For: Jun 01

Mon, 01 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26583528.html

Form 8-K IDEAYA Biosciences, Inc. For: Jun 01

Mon, 01 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26583528.html

IDEAYA reports positive phase 2/3 trial results for uveal melanoma drug